{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:11:35Z","timestamp":1791810695294,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-024-03432-4","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T08:33:31Z","timestamp":1735893211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender"],"prefix":"10.1186","volume":"27","author":[{"given":"Nicoletta","family":"Luciano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Brunetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"D\u2019Isanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo M.","family":"Guidelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Renna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"1","key":"3432_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, Van Der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33004335\/. [cited 2023 Nov 27].\u00a0","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"3432_CR2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","volume":"77","author":"NMT Roodenrijs","year":"2018","unstructured":"Roodenrijs NMT, De Hair MJH, Van Der Goes MC, Jacobs JWG, Welsing PMJ, Van Der Heijde D, et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018;77(12):1705\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30194273\/.\u00a0[cited 2023 Nov 27].","journal-title":"Ann Rheum Dis."},{"key":"3432_CR3","unstructured":"MJH de H, JWG J, JLM S, JM van L. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57(7). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29029308\/. [cited 2023 Nov 27]."},{"issue":"1","key":"3432_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/25785826.2021.1928383","volume":"45","author":"R Watanabe","year":"2022","unstructured":"Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ohmura K, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2022;45(1):35\u201344. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34033729\/. [cited 2023 Nov 27].\u00a0","journal-title":"Immunol Med."},{"issue":"9","key":"3432_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s10067-019-04579-1","volume":"38","author":"B Batko","year":"2019","unstructured":"Batko B, Urba\u0144ski K, \u015awierkot J, Wiland P, Raciborski F, J\u0119drzejewski M, et al. Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. Clin Rheumatol. 2019;38(9):2473\u201381. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31076943\/. [cited 2023 Nov 27].\u00a0","journal-title":"Clin Rheumatol."},{"issue":"9","key":"3432_CR6","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1093\/rheumatology\/keac114","volume":"61","author":"NMT Roodenrijs","year":"2022","unstructured":"Roodenrijs NMT, Welsing PMJ, Van Roon J, Schoneveld JLM, Van Der Goes MC, Nagy G, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology (Oxford). 2022;61(9):3552\u201366. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35238332\/. [cited 2023 Nov 27].","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"3432_CR7","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/rheumatology\/keac563","volume":"62","author":"A Giollo","year":"2023","unstructured":"Giollo A, Zen M, Larosa M, Astorri D, Salvato M, Calligaro A, et al. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study. Rheumatology (Oxford). 2023;62(6):2083\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36190344\/. [cited 2023 Nov 27].\u00a0","journal-title":"Rheumatology (Oxford)."},{"key":"3432_CR8","doi-asserted-by":"crossref","unstructured":"Roodenrijs NMT, Kedves M, Hamar A, Nagy G, Van Laar JM, Van Der Heijde D, et al. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021;7(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33514671\/. [cited 2023 Nov 27].","DOI":"10.1136\/rmdopen-2020-001511"},{"issue":"3","key":"3432_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-023-08975-z","volume":"65","author":"N Luciano","year":"2023","unstructured":"Luciano N, Barone E, Timilsina S, Gershwin ME, Selmi C. Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis. Clin Rev Allergy Immunol. 2023;65(3):403\u201319. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38157095\/. [cited 2024 Sep 9].\u00a0","journal-title":"Clin Rev Allergy Immunol."},{"issue":"10","key":"3432_CR10","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1093\/rheumatology\/keac134","volume":"61","author":"M Dey","year":"2022","unstructured":"Dey M, Nagy G, Nikiphorou E. Comorbidities or extra-articular manifestations: time to reconsider the terminology? Rheumatology (Oxford). 2022;61(10):3881\u20133. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35244149\/. [cited 2023 Nov 27].\u00a0","journal-title":"Rheumatology (Oxford)."},{"key":"3432_CR11","doi-asserted-by":"crossref","unstructured":"Messelink MA, Roodenrijs NMT, van Es B, Hulsbergen-Veelken CAR, Jong S, Overmars LM, et al. Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon. Arthritis Res Ther. 2021;23(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34238346\/. [cited 2023 Nov 27].","DOI":"10.1186\/s13075-021-02560-5"},{"key":"3432_CR12","doi-asserted-by":"crossref","unstructured":"Hecquet S, Combier A, Steelandt A, Pons M, Wendling D, Molto A, et al. Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital. Rheumatology (Oxford). 2023. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36961324\/. [cited 2023 Nov 27].","DOI":"10.1093\/rheumatology\/kead143"},{"key":"3432_CR13","doi-asserted-by":"crossref","unstructured":"Novella-Navarro M, Plasencia C, Tornero C, Navarro-Comp\u00e1n V, Cabrera-Alarc\u00f3n JL, Peiteado-L\u00f3pez D, et al. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33298140\/. [cited 2024 Feb 10].","DOI":"10.1186\/s13075-020-02354-1"},{"key":"3432_CR14","doi-asserted-by":"crossref","unstructured":"Kay J, Upchurch KS. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51 Suppl 6(SUPPL. 6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23221588\/. [cited 2023 Nov 27].","DOI":"10.1093\/rheumatology\/kes279"},{"issue":"3","key":"3432_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","volume":"46","author":"F Wolfe","year":"2016","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, H\u00e4user W, Katz RL, et al. 2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016Dec 1;46(3):319\u201329.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3432_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","volume":"81","author":"G Nagy","year":"2022","unstructured":"Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20\u201333. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34407926\/. [cited 2023 Nov 27].\u00a0","journal-title":"Ann Rheum Dis."},{"key":"3432_CR17","doi-asserted-by":"crossref","unstructured":"Tan Y, Buch MH. \u201cDifficult to treat\u201d rheumatoid arthritis: current position and considerations for next steps. RMD Open. 2022;8(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35896282\/.\u00a0[cited 2023 Nov 26].","DOI":"10.1136\/rmdopen-2022-002387"},{"issue":"8","key":"3432_CR18","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1093\/rheumatology\/keaa860","volume":"60","author":"NMT Roodenrijs","year":"2021","unstructured":"Roodenrijs NMT, Van Der Goes MC, Welsing PMJ, Tekstra J, Lafeber FPJG, Jacobs JWG, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford). 2021;60(8):3778\u201388. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33331946\/.[cited 2023 Nov 27].\u00a0","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"3432_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","volume":"17","author":"MH Buch","year":"2021","unstructured":"Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17\u201333. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33293696\/. [cited 2023 Nov 27].","journal-title":"Nat Rev Rheumatol."},{"key":"3432_CR20","doi-asserted-by":"crossref","unstructured":"Joharatnam N, McWilliams DF, Wilson D, Wheeler M, Pande I, Walsh DA. A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis. Arthritis Res Ther. 2015;17(1). Available from: https:\/\/www.pmc\/articles\/PMC4363056\/. [cited 2024 Feb 10].","DOI":"10.1186\/s13075-015-0525-5"},{"key":"3432_CR21","doi-asserted-by":"crossref","unstructured":"Majnik J, Cs\u00e1sz\u00e1r-Nagy N, B\u00f6cskei G, Bender T, Nagy G. Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis. Front Med (Lausanne). 2022;9. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36106320\/. [cited 2024 Sep 17].","DOI":"10.3389\/fmed.2022.991677"},{"key":"3432_CR22","doi-asserted-by":"crossref","unstructured":"Novella-Navarro M, Cabrera-Alarc\u00f3n J, L\u00f3pez-Juanes N, Villalba A, Fern\u00e1ndez EF, Monjo I, et al. Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b\/tsDMARD treatment. RMD Open. 2023;9(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37775112\/. [cited 2024 Sep 17].","DOI":"10.1136\/rmdopen-2023-003382"},{"issue":"5","key":"3432_CR23","first-page":"1114","volume":"41","author":"M Novella-Navarro","year":"2023","unstructured":"Novella-Navarro M, Ruiz-Esquide V, Torres-Ortiz G, Chacur CA, Tornero C, Fern\u00e1ndez-Fernandez E, et al. A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification. Clin Exp Rheumatol. 2023;41(5):1114\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36377568\/. [cited 2024 Sep 17].\u00a0","journal-title":"Clin Exp Rheumatol."},{"issue":"1","key":"3432_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/acr.21710","volume":"65","author":"S Ajeganova","year":"2013","unstructured":"Ajeganova S, Andersson ML, Hafstr\u00f6m I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res (Hoboken). 2013;65(1):78\u201387. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22514159\/\u00a0. [cited 2023 Nov 27].","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"3432_CR25","doi-asserted-by":"crossref","unstructured":"Abuhelwa AY, Hopkins AM, Sorich MJ, Proudman S, Foster DJR, Wiese MD. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Sci Rep. 2020;10(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33122725\/. [cited 2023 Nov 27].\u00a0","DOI":"10.1038\/s41598-020-75673-7"},{"issue":"1","key":"3432_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/acr.21768","volume":"65","author":"E Gremese","year":"2013","unstructured":"Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor \u03b1 in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken). 2013;65(1):94\u2013100. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22730143\/. [cited 2023 Nov 27].\u00a0","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"3432_CR27","first-page":"458","volume":"3","author":"A Levitsky","year":"2017","unstructured":"Levitsky A, Brismar K, Hafstr\u00f6m I, Hambardzumyan K, Lourdudoss C, Van Vollenhoven RF, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. Open. 2017;3:458. Available from: http:\/\/rmdopen.bmj.com\/. [cited 2023 Nov 27].\u00a0","journal-title":"Open."},{"key":"3432_CR28","doi-asserted-by":"crossref","unstructured":"Del Prete A, Salvi V, Sozzani S. Adipokines as potential biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014 . Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24799765\/. [cited 2023 Nov 27].","DOI":"10.1155\/2014\/425068"},{"issue":"9","key":"3432_CR29","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/art.24789","volume":"61","author":"JT Giles","year":"2009","unstructured":"Giles JT, Allison M, Bingham CO, Scott WM, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum. 2009;61(9):1248\u201356. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19714593\/. [cited 2023 Nov 27].","journal-title":"Arthritis Rheum."},{"issue":"1","key":"3432_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cytogfr.2012.07.004","volume":"24","author":"X Chen","year":"2013","unstructured":"Chen X, Lu J, Bao J, Guo J, Shi J, Wang Y. Adiponectin: a biomarker for rheumatoid arthritis? Cytokine Growth Factor Rev. 2013;24(1):83\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22910140\/. [cited 2023 Nov 27].","journal-title":"Cytokine Growth Factor Rev."},{"key":"3432_CR31","doi-asserted-by":"crossref","unstructured":"Meyer M, Sellam J, Fellahi S, Kotti S, Bastard JP, Meyer O, et al. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther. 2013;15(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24314299\/. [cited 2023 Nov 27].","DOI":"10.1186\/ar4404"},{"issue":"3","key":"3432_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00296-010-1698-5","volume":"32","author":"SM Olama","year":"2012","unstructured":"Olama SM, Senna MK, Elarman M. Synovial\/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatol Int. 2012;32(3):683\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21140264\/. [cited 2023 Nov 27].","journal-title":"Rheumatol Int."},{"issue":"2","key":"3432_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4078\/jrd.2023.0005","volume":"30","author":"YH Lee","year":"2023","unstructured":"Lee YH, Song GG. Circulating leptin and its correlation with rheumatoid arthritis activity: a meta-analysis. J Rheum Dis. 2023;30(2):116\u201325. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37483475\/. [cited 2023 Nov 28].\u00a0","journal-title":"J Rheum Dis."},{"issue":"5","key":"3432_CR34","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","volume":"62","author":"M Dey","year":"2023","unstructured":"Dey M, Nagy G, Nikiphorou E. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology (Oxford). 2023;62(5):1773\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36205537\/. [cited 2024 Sep 17].","journal-title":"Rheumatology (Oxford)."},{"key":"3432_CR35","doi-asserted-by":"crossref","unstructured":"Bertsias A, Flouri ID, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S, et al. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with \u201cdifficult to treat\u201d rheumatoid arthritis. RMD Open. 2024;10(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38242549\/. [cited 2024 Sep 17].","DOI":"10.1136\/rmdopen-2023-003808"},{"issue":"12","key":"3432_CR36","doi-asserted-by":"publisher","first-page":"22279","DOI":"10.3390\/ijms151222279","volume":"15","author":"K Chang","year":"2014","unstructured":"Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JIl. Smoking and rheumatoid arthritis. Int J Mol Sci. 2014;15(12):22279\u201395. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25479074\/. [cited 2023 Nov 27].\u00a0","journal-title":"Int J Mol Sci."},{"key":"3432_CR37","doi-asserted-by":"crossref","unstructured":"Ishikawa Y, Terao C. The Impact of Cigarette Smoking on Risk of Rheumatoid Arthritis: A Narrative Review. Cells. 2020;9(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32092988\/. [cited 2023 Nov 27].","DOI":"10.3390\/cells9020475"},{"issue":"4","key":"3432_CR38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3899\/jrheum.180262","volume":"46","author":"MA Gianfrancesco","year":"2019","unstructured":"Gianfrancesco MA, Trupin L, Shiboski S, Van Der Laan M, Graf J, Imboden J, et al. Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates. J Rheumatol. 2019;46(4):370\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30504507\/. [cited 2023 Nov 27].\u00a0","journal-title":"J Rheumatol."},{"issue":"8","key":"3432_CR39","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/rheumatology\/kez557","volume":"59","author":"IK Roelsgaard","year":"2020","unstructured":"Roelsgaard IK, Ikdahl E, Rollefstad S, Wibetoe G, Esbensen BA, Kitas GD, et al. Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. Rheumatology (Oxford). 2020;59(8):1997\u20132004. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31782789\/. [cited 2023 Nov 27].\u00a0","journal-title":"Rheumatology (Oxford)."},{"key":"3432_CR40","doi-asserted-by":"crossref","unstructured":"Nayebirad S, Javinani A, Javadi M, Yousefi-Koma H, Farahmand K, Atef Yekta R, et al. The effect of smoking on response to methotrexate in rheumatoid arthritis patients: A systematic review and meta-analysis. Mod Rheumatol. 2023. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36688574\/. [cited 2023 Nov 27].","DOI":"10.1093\/mr\/road013"},{"issue":"10","key":"3432_CR41","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s00296-023-05349-8","volume":"43","author":"R Garcia-Salinas","year":"2023","unstructured":"Garcia-Salinas R, Sanchez-Prado E, Mareco J, Ronald P, Ruta S, Gomez R, et al. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations. Rheumatol Int. 2023;43(10):1821\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37269430\/. [cited 2024 Sep 17].\u00a0","journal-title":"Rheumatol Int."},{"issue":"7","key":"3432_CR42","first-page":"1398","volume":"42","author":"G Alp","year":"2024","unstructured":"Alp G, Cinakli H, Aysin \u0130K, Solmaz D, Akar S. Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives. Clin Exp Rheumatol. 2024;42(7):1398\u2013406. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38372714\/. [cited 2024 Sep 17].\u00a0","journal-title":"Clin Exp Rheumatol."},{"key":"3432_CR43","doi-asserted-by":"crossref","unstructured":"Fautrel B, Kirkham B, Pope JE, Takeuchi T, Gaich C, Quebe A, et al. Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. J Clin Med. 2019;8(9). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31492040\/\u00a0. [cited 2023 Nov 27].","DOI":"10.3390\/jcm8091394"},{"key":"3432_CR44","doi-asserted-by":"crossref","unstructured":"Dougados M, Taylor PC, Bingham CO, Fallon L, Brault Y, Roychoudhury S, et al. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022;8(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36814062\/. [cited 2023 Nov 27].","DOI":"10.1136\/rmdopen-2022-002478"},{"issue":"6","key":"3432_CR45","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11739-023-03350-4","volume":"18","author":"L De Stefano","year":"2023","unstructured":"De Stefano L, Bozzalla Cassione E, Bottazzi F, Marazzi E, Maggiore F, Morandi V, et al. Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis. Intern Emerg Med. 2023;18(6):1733\u20134. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37500945\/. [cited 2023 Nov 27].\u00a0","journal-title":"Intern Emerg Med."},{"issue":"1","key":"3432_CR46","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","volume":"51","author":"LS Simon","year":"2021","unstructured":"Simon LS, Taylor PC, Choy EH, Sebba A, Quebe A, Knopp KL, et al. The Jak\/STAT pathway: A focus on pain in rheumatoid arthritis. Semin Arthritis Rheum. 2021;51(1):278\u201384. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33412435\/. [cited 2023 Nov 27].\u00a0","journal-title":"Semin Arthritis Rheum."},{"key":"3432_CR47","doi-asserted-by":"crossref","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022;24(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35232462\/. [cited 2023 Nov 27].","DOI":"10.1186\/s13075-022-02744-7"},{"issue":"11","key":"3432_CR48","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1093\/rheumatology\/keab130","volume":"60","author":"NMT Roodenrijs","year":"2021","unstructured":"Roodenrijs NMT, Van Der Goes MC, Welsing PMJ, Van Oorschot EPC, Nikiphorou E, Nijhof NC, et al. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology (Oxford). 2021;60(11):5105\u201316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33560301\/. [cited 2023 Nov 27].\u00a0","journal-title":"Rheumatology (Oxford)."},{"issue":"4","key":"3432_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1586\/eci.12.23","volume":"8","author":"BJF Van Den Bemt","year":"2012","unstructured":"Van Den Bemt BJF, Zwikker HE, Van Den Ende CHM. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8(4):337\u201351. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22607180\/. [cited 2023 Nov 27].\u00a0","journal-title":"Expert Rev Clin Immunol."},{"issue":"5","key":"3432_CR50","first-page":"1114","volume":"41","author":"M Novella-Navarro","year":"2023","unstructured":"Novella-Navarro M, Ruiz-Esquide V, Torres-Ortiz G, Chacur CA, Tornero C, Fern\u00e1ndez-Fernandez E, et al. A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification. Clin Exp Rheumatol. 2023;41(5):1114\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36377568\/. [cited 2024 Sep 17].\u00a0","journal-title":"Clin Exp Rheumatol."},{"issue":"10271","key":"3432_CR51","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397(10271):305\u201317. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33485455\/. [cited 2023 Nov 27].\u00a0","journal-title":"Lancet."},{"issue":"11","key":"3432_CR52","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","volume":"5","author":"F Rivellese","year":"2023","unstructured":"Rivellese F, Nerviani A, Giorli G, Warren L, Jaworska E, Bombardieri M, et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 2023;5(11):e648\u201359. Available from: http:\/\/www.thelancet.com\/article\/S2665991323002412\/fulltext\u00a0. [cited 2023 Nov 27].\u00a0","journal-title":"Lancet Rheumatol."},{"issue":"10","key":"3432_CR53","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","volume":"16","author":"C Pitzalis","year":"2020","unstructured":"Pitzalis C, Choy EHS, Buch MH. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nature Rev Rheumatol. 2020;16(10):590\u20139. Available from: https:\/\/www.nature.com\/articles\/s41584-020-0491-4. [cited 2024 Feb 1].\u00a0","journal-title":"Nature Rev Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03432-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:05:00Z","timestamp":1735895100000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03432-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3432"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03432-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.L. and G.M.G.: Consulting \/ speakers fee AbbVie, BMS, Eli-Lilly, Galapagos, Janssen, Novartis; D.R.: Consulting \/ speakers fee AbbVie, Eli-Lilly, Janssen, Novartis; C.S.: Consulting \/ speakers fee (AbbVie, Amgen, Alfa-Wassermann, Biogen, Eli-Lilly, Galapagos, Janssen, Novartis, Pfizer, SOBI); Research support (AbbVie, Amgen, Pfizer).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}